Across TCGA pan-cancer cohorts, AFF4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AFF4 data layer compared with 22 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AFF4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AFF4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.
LUAD, HNSC, and CCRCC are the cancer types where AFF4 mass-spec protein most reproducibly stratifies survival.